Another phase I open-label clinical trial conducted in 56 EGFR TKI-naïve NSCLC patients observed higher toxicity profiles in patients receiving the combination treatment than in those receiving either drug alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.